

HB 1323

2022

1                                   A bill to be entitled  
 2           An act relating to pharmaceutical products containing  
 3           cannabis; amending s. 893.03, F.S.; excluding cannabis  
 4           from Schedule I listing if it is contained within a  
 5           pharmaceutical product approved by the United States  
 6           Food and Drug Administration; providing construction;  
 7           providing an effective date.  
 8

9   Be It Enacted by the Legislature of the State of Florida:  
 10

11           Section 1. Paragraph (c) of subsection (1) of section  
 12   893.03, Florida Statutes, is amended to read:

13           893.03 Standards and schedules.—The substances enumerated  
 14   in this section are controlled by this chapter. The controlled  
 15   substances listed or to be listed in Schedules I, II, III, IV,  
 16   and V are included by whatever official, common, usual,  
 17   chemical, trade name, or class designated. The provisions of  
 18   this section shall not be construed to include within any of the  
 19   schedules contained in this section any excluded drugs listed  
 20   within the purview of 21 C.F.R. s. 1308.22, styled "Excluded  
 21   Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical  
 22   Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted  
 23   Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt  
 24   Anabolic Steroid Products."

25           (1) SCHEDULE I.—A substance in Schedule I has a high

HB 1323

2022

26 | potential for abuse and has no currently accepted medical use in  
 27 | treatment in the United States and in its use under medical  
 28 | supervision does not meet accepted safety standards. The  
 29 | following substances are controlled in Schedule I:

30 |       (c) Unless specifically excepted or unless listed in  
 31 | another schedule, any material, compound, mixture, or  
 32 | preparation that contains any quantity of the following  
 33 | hallucinogenic substances or that contains any of their salts,  
 34 | isomers, including optical, positional, or geometric isomers,  
 35 | homologues, nitrogen-heterocyclic analogs, esters, ethers, and  
 36 | salts of isomers, homologues, nitrogen-heterocyclic analogs,  
 37 | esters, or ethers, if the existence of such salts, isomers, and  
 38 | salts of isomers is possible within the specific chemical  
 39 | designation or class description:

- 40 |       1. Alpha-Ethyltryptamine.
- 41 |       2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-  
 42 | oxazoline).
- 43 |       3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 44 |       4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 45 |       5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 46 |       6. Bufotenine.
- 47 |       7. Cannabis, except if it is contained within a  
 48 | pharmaceutical product approved by the United States Food and  
 49 | Drug Administration.
- 50 |       8. Cathinone.

HB 1323

2022

- 51 | 9. DET (Diethyltryptamine).
- 52 | 10. 2,5-Dimethoxyamphetamine.
- 53 | 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 54 | 12. DMT (Dimethyltryptamine).
- 55 | 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
- 56 | analog of phencyclidine).
- 57 | 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
- 58 | 15. N-Ethylamphetamine.
- 59 | 16. Fenethylamine.
- 60 | 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 61 | 18. Ibogaine.
- 62 | 19. LSD (Lysergic acid diethylamide).
- 63 | 20. Mescaline.
- 64 | 21. Methcathinone.
- 65 | 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 66 | 23. PMA (4-Methoxyamphetamine).
- 67 | 24. PMMA (4-Methoxymethamphetamine).
- 68 | 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 69 | 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 70 | 27. MDA (3,4-Methylenedioxyamphetamine).
- 71 | 28. JB-336 (N-Methyl-3-piperidyl benzilate).
- 72 | 29. N,N-Dimethylamphetamine.
- 73 | 30. Parahexyl.
- 74 | 31. Peyote.
- 75 | 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine

HB 1323

2022

- 76 | analog of phencyclidine).
- 77 |       33. Psilocybin.
- 78 |       34. Psilocyn.
- 79 |       35. *Salvia divinorum*, except for any drug product approved
- 80 | by the United States Food and Drug Administration which contains
- 81 | *Salvia divinorum* or its isomers, esters, ethers, salts, and
- 82 | salts of isomers, esters, and ethers, if the existence of such
- 83 | isomers, esters, ethers, and salts is possible within the
- 84 | specific chemical designation.
- 85 |       36. Salvinorin A, except for any drug product approved by
- 86 | the United States Food and Drug Administration which contains
- 87 | Salvinorin A or its isomers, esters, ethers, salts, and salts of
- 88 | isomers, esters, and ethers, if the existence of such isomers,
- 89 | esters, ethers, and salts is possible within the specific
- 90 | chemical designation.
- 91 |       37. Xylazine.
- 92 |       38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
- 93 | (Thiophene analog of phencyclidine).
- 94 |       39. 3,4,5-Trimethoxyamphetamine.
- 95 |       40. Methydone (3,4-Methylenedioxyamphetaminone).
- 96 |       41. MDPV (3,4-Methylenedioxypropionylphenone).
- 97 |       42. Methylenedioxymethamphetamine.
- 98 |       43. Methoxyamphetaminone.
- 99 |       44. Fluoromethylenedioxymethamphetamine.
- 100 |       45. Methylenedioxymethamphetamine.

HB 1323

2022

- 101 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-  
 102 yl)phenol) and its dimethyloctyl (C8) homologue.
- 103 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
 104 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
 105 ol].
- 106 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
- 107 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
- 108 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-  
 109 naphthoyl)indole).
- 110 51. BZP (Benzylpiperazine).
- 111 52. Fluorophenylpiperazine.
- 112 53. Methylphenylpiperazine.
- 113 54. Chlorophenylpiperazine.
- 114 55. Methoxyphenylpiperazine.
- 115 56. DBZP (1,4-Dibenzylpiperazine).
- 116 57. TFMPP (Trifluoromethylphenylpiperazine).
- 117 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-  
 118 Methylenedioxy-N-methylbutanamine).
- 119 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 120 60. 5-Hydroxy-N-methyltryptamine.
- 121 61. 5-MeO-MIPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 122 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 123 63. Methyltryptamine.
- 124 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 125 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).

HB 1323

2022

- 126 | 66. Tyramine (4-Hydroxyphenethylamine).
- 127 | 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 128 | 68. DiPT (N,N-Diisopropyltryptamine).
- 129 | 69. DPT (N,N-Dipropyltryptamine).
- 130 | 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 131 | 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 132 | 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 133 | 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 134 | 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 135 | 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 136 | 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 137 | 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 138 | 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 139 | 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 140 | 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 141 | 81. Butylone (3,4-Methylenedioxy-alpha-
- 142 | methylaminobutyrophenone).
- 143 | 82. Ethcathinone.
- 144 | 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 145 | 84. Naphyrone (Naphthylpyrovalerone).
- 146 | 85. Dimethylone (3,4-Methylenedioxy-N,N-
- 147 | dimethylcathinone).
- 148 | 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
- 149 | 87. 3,4-Methylenedioxy-propiofenone.
- 150 | 88. 3,4-Methylenedioxy-alpha-bromopropiofenone.

HB 1323

2022

- 151 | 89. 3,4-Methylenedioxy-propiofenone-2-oxime.
- 152 | 90. 3,4-Methylenedioxy-N-acetylcathinone.
- 153 | 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
- 154 | 92. 3,4-Methylenedioxy-N-acetylethcathinone.
- 155 | 93. Bromomethcathinone.
- 156 | 94. Buphedrone (alpha-Methylamino-butyrophenone).
- 157 | 95. Eutylone (3,4-Methylenedioxy-alpha-
- 158 | ethylaminobutyrophenone).
- 159 | 96. Dimethylcathinone.
- 160 | 97. Dimethylmethcathinone.
- 161 | 98. Pentylone (3,4-Methylenedioxy-alpha-
- 162 | methylaminovalerophenone).
- 163 | 99. MDPPP (3,4-Methylenedioxy-alpha-
- 164 | pyrrolidinopropiofenone).
- 165 | 100. MDPBP (3,4-Methylenedioxy-alpha-
- 166 | pyrrolidinobutyrophenone).
- 167 | 101. MOPPP (Methoxy-alpha-pyrrolidinopropiofenone).
- 168 | 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 169 | 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
- 170 | (Benocyclidine).
- 171 | 104. F-MABP (Fluoromethylaminobutyrophenone).
- 172 | 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 173 | 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
- 174 | 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
- 175 | 108. Me-EABP (Methylethylaminobutyrophenone).

HB 1323

2022

- 176 |           109. Etizolam.
- 177 |           110. PPP (Pyrrolidinopropiophenone).
- 178 |           111. PBP (Pyrrolidinobutyrophenone).
- 179 |           112. PVP (Pyrrolidinovalerophenone) or
- 180 | (Pyrrolidinopentiophenone).
- 181 |           113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 182 |           114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl) indole).
- 183 |           115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl) indole).
- 184 |           116. JWH-019 (1-Hexyl-3-(1-naphthoyl) indole).
- 185 |           117. JWH-020 (1-Heptyl-3-(1-naphthoyl) indole).
- 186 |           118. JWH-072 (1-Propyl-3-(1-naphthoyl) indole).
- 187 |           119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl) indole).
- 188 |           120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole).
- 189 |           121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-
- 190 | methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
- 191 |           122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl) indole).
- 192 |           123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl) indole).
- 193 |           124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole).
- 194 |           125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl) indole).
- 195 |           126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole).
- 196 |           127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl) indole).
- 197 |           128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl) indole).
- 198 |           129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole).
- 199 |           130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
- 200 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-



HB 1323

2022

- 201 ol).
- 202 131. HU-308 ([ (1R,2R,5R) -2-[2,6-Dimethoxy-4-(2-
- 203 methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-
- 204 enyl] methanol).
- 205 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-
- 206 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-
- 207 1,4-dione).
- 208 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
- 209 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-
- 210 undecanamide).
- 211 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-
- 212 undecanamide).
- 213 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-
- 214 methyloctan-2-yl)phenol).
- 215 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
- 216 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
- 217 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
- 218 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
- 219 methoxyphenylacetyl)indole).
- 220 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
- 221 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
- 222 naphthalenylmethanone).
- 223 142. WIN55,212-3 ([ (3S)-2,3-Dihydro-5-methyl-3-(4-
- 224 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
- 225 naphthalenylmethanone).

HB 1323

2022

- 226 | 143. Pentedrone (alpha-Methylaminovalerophenone).
- 227 | 144. Fluoroamphetamine.
- 228 | 145. Fluoromethamphetamine.
- 229 | 146. Methoxetamine.
- 230 | 147. Methiopropamine.
- 231 | 148. Methylbuphedrone (Methyl-alpha-
- 232 | methylaminobutyrophenone) .
- 233 | 149. APB ((2-Aminopropyl)benzofuran) .
- 234 | 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran) .
- 235 | 151. UR-144 (1-Pentyl-3-(2,2,3,3-
- 236 | tetramethylcyclopropanoyl)indole) .
- 237 | 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
- 238 | tetramethylcyclopropanoyl)indole) .
- 239 | 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
- 240 | tetramethylcyclopropanoyl)indole) .
- 241 | 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-
- 242 | carboxamide) .
- 243 | 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
- 244 | iodobenzoyl)indole) .
- 245 | 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
- 246 | carboxamide) .
- 247 | 157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-
- 248 | cyclohexylcarbamate) .
- 249 | 158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid,
- 250 | cyclohexyl ester) .

HB 1323

2022

- 251 159. URB-754 (6-Methyl-2-[(4-methylphenyl) amino]-1-  
 252 benzoxazin-4-one) .
- 253 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine) .
- 254 161. 2C-H (2,5-Dimethoxyphenethylamine) .
- 255 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
- 256 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .
- 257 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-  
 258 methoxybenzyl)]phenethylamine) .
- 259 165. MDMA (3,4-Methylenedioxyamphetamine) .
- 260 166. PB-22 (8-Quinolinyll 1-pentylindole-3-carboxylate) .
- 261 167. Fluoro PB-22 (8-Quinolinyll 1-(fluoropentyl)indole-3-  
 262 carboxylate) .
- 263 168. BB-22 (8-Quinolinyll 1-(cyclohexylmethyl)indole-3-  
 264 carboxylate) .
- 265 169. Fluoro AKB48 (N-Adamant-1-yl 1-  
 266 (fluoropentyl)indazole-3-carboxamide) .
- 267 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
 268 pentylindazole-3-carboxamide) .
- 269 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
 270 (4-fluorobenzyl)indazole-3-carboxamide) .
- 271 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-  
 272 1-pentylindazole-3-carboxamide) .
- 273 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
 274 yl)-1-(fluoropentyl)indole-3-carboxamide) .
- 275 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-

HB 1323

2022

276 methoxybenzyl) ]phenethylamine) .  
277 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy- [N- (2-  
278 methoxybenzyl) ]phenethylamine) .  
279 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl) -1-  
280 (cyclohexylmethyl) indazole-3-carboxamide) .  
281 177. FUB-PB-22 (8-Quinoliny 1- (4-fluorobenzyl) indole-3-  
282 carboxylate) .  
283 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-  
284 (fluoropentyl) indole-3-carboxamide) .  
285 179. Fluoro-AMB (N- (1-Methoxy-3-methyl-1-oxobutan-2-yl) -1-  
286 (fluoropentyl) indazole-3-carboxamide) .  
287 180. THJ-2201 (1- (5-Fluoropentyl) -3- (1-  
288 naphthoyl) indazole) .  
289 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-  
290 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol) .  
291 182. AM-905 ((6aR,9R,10aR)-3- [(E)-Hept-1-enyl] -9-  
292 (hydroxymethyl) -6,6-dimethyl-6a,7,8,9,10,10a-  
293 hexahydrobenzo[c]chromen-1-ol) .  
294 183. AM-906 ((6aR,9R,10aR)-3- [(Z)-Hept-1-enyl] -9-  
295 (hydroxymethyl) -6,6-dimethyl-6a,7,8,9,10,10a-  
296 hexahydrobenzo[c]chromen-1-ol) .  
297 184. AM-2389 ((6aR,9R,10aR)-3- (1-Hexyl-cyclobut-1-yl) -  
298 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9  
299 diol) .  
300 185. HU-243 ((6aR,8S,9S,10aR)-9- (Hydroxymethyl) -6,6-

HB 1323

2022

301 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-  
 302 tetrahydro-6aH-benzo[c]chromen-1-ol).

303 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-  
 304 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

305 187. MAPB ((2-Methylaminopropyl)benzofuran).

306 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

307 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

308 190. Synthetic Cannabinoids.—Unless specifically excepted  
 309 or unless listed in another schedule or contained within a  
 310 pharmaceutical product approved by the United States Food and  
 311 Drug Administration, any material, compound, mixture, or  
 312 preparation that contains any quantity of a synthetic  
 313 cannabinoid found to be in any of the following chemical class  
 314 descriptions, or homologues, nitrogen-heterocyclic analogs,  
 315 isomers (including optical, positional, or geometric), esters,  
 316 ethers, salts, and salts of homologues, nitrogen-heterocyclic  
 317 analogs, isomers, esters, or ethers, whenever the existence of  
 318 such homologues, nitrogen-heterocyclic analogs, isomers, esters,  
 319 ethers, salts, and salts of isomers, esters, or ethers is  
 320 possible within the specific chemical class or designation.  
 321 Since nomenclature of these synthetically produced cannabinoids  
 322 is not internationally standardized and may continually evolve,  
 323 these structures or the compounds of these structures shall be  
 324 included under this subparagraph, regardless of their specific  
 325 numerical designation of atomic positions covered, if it can be

HB 1323

2022

326 | determined through a recognized method of scientific testing or  
 327 | analysis that the substance contains properties that fit within  
 328 | one or more of the following categories:

329 |       a. Tetrahydrocannabinols.—Any tetrahydrocannabinols  
 330 | naturally contained in a plant of the genus *Cannabis*, the  
 331 | synthetic equivalents of the substances contained in the plant  
 332 | or in the resinous extracts of the genus *Cannabis*, or synthetic  
 333 | substances, derivatives, and their isomers with similar chemical  
 334 | structure and pharmacological activity, including, but not  
 335 | limited to, Delta 9 tetrahydrocannabinols and their optical  
 336 | isomers, Delta 8 tetrahydrocannabinols and their optical  
 337 | isomers, Delta 6a,10a tetrahydrocannabinols and their optical  
 338 | isomers, or any compound containing a tetrahydrobenzo[c]chromene  
 339 | structure with substitution at either or both the 3-position or  
 340 | 9-position, with or without substitution at the 1-position with  
 341 | hydroxyl or alkoxy groups, including, but not limited to:

342 |       (I) Tetrahydrocannabinol.

343 |       (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
 344 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
 345 | ol).

346 |       (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
 347 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
 348 | ol).

349 |       (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
 350 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

HB 1323

2022

351 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-  
352 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

353 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-  
354 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

355 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-  
356 (2,3-dimethylpentan-2-yl)-6a,7,10,10a-  
357 tetrahydrobenzo[c]chromene).

358 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-  
359 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

360 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-  
361 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

362 (X) Parahexyl.

363 b. Naphthoylindoles, Naphthoylindazoles,  
364 Naphthoylcarbazoles, Naphthylmethylindoles,  
365 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any  
366 compound containing a naphthoylindole, naphthoylindazole,  
367 naphthoylcarbazole, naphthylmethylindole,  
368 naphthylmethylindazole, or naphthylmethylcarbazole structure,  
369 with or without substitution on the indole, indazole, or  
370 carbazole ring to any extent, whether or not substituted on the  
371 naphthyl ring to any extent, including, but not limited to:

372 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).

373 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-  
374 naphthoyl)indole).

375 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).

HB 1323

2022

- 376 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl) indole).  
 377 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl) indole).  
 378 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl) indole).  
 379 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl) indole).  
 380 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl) indole).  
 381 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl) indole).  
 382 (X) JWH-072 (1-Propyl-3-(1-naphthoyl) indole).  
 383 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl) indole).  
 384 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl) indole).  
 385 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl) indole).  
 386 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-  
 387 naphthoyl) indole).  
 388 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl) indole).  
 389 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole).  
 390 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-  
 391 naphthoyl) indole).  
 392 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-  
 393 naphthoyl) indole).  
 394 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl) indole).  
 395 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl) indole).  
 396 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl) indole).  
 397 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-  
 398 naphthylmethyl] indole).  
 399 (XXIII) JWH-193 (1-[2-(4-Morpholinyl) ethyl]-3-(4-methyl-1-  
 400 naphthoyl) indole).



HB 1323

2022

401 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-  
 402 naphthoyl)indole).  
 403 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-  
 404 naphthoyl)indole).  
 405 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).  
 406 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).  
 407 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-  
 408 naphthoyl)indole).  
 409 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).  
 410 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).  
 411 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-  
 412 naphthoyl)indole).  
 413 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-  
 414 naphthoyl)indole).  
 415 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-  
 416 naphthoyl)indole).  
 417 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-  
 418 naphthoyl)indole).  
 419 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-  
 420 naphthoyl)indole).  
 421 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).  
 422 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-  
 423 naphthoyl)indazole).  
 424 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-  
 425 naphthoyl)indole).

HB 1323

2022

426 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-  
 427 naphthoyl)indole).

428 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).

429 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-  
 430 naphthoyl)carbazole).

431 c. Naphthoylpyrroles.—Any compound containing a  
 432 naphthoylpyrrole structure, with or without substitution on the  
 433 pyrrole ring to any extent, whether or not substituted on the  
 434 naphthyl ring to any extent, including, but not limited to:

435 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).

436 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).

437 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).

438 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).

439 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).

440 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-  
 441 naphthoyl)pyrrole).

442 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-  
 443 naphthoyl)pyrrole).

444 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-  
 445 naphthoyl)pyrrole).

446 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-  
 447 naphthoyl)pyrrole).

448 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-  
 449 naphthoyl)pyrrole).

450 d. Naphthylmethylenindenes.—Any compound containing a

HB 1323

2022

451 naphthylmethylenindene structure, with or without substitution  
 452 at the 3-position of the indene ring to any extent, whether or  
 453 not substituted on the naphthyl ring to any extent, including,  
 454 but not limited to, JWH-176 (3-Pentyl-1-  
 455 (naphthylmethylene)indene).

456 e. Phenylacetylindoles and Phenylacetylindazoles.—Any  
 457 compound containing a phenylacetylindole or phenylacetylindazole  
 458 structure, with or without substitution on the indole or  
 459 indazole ring to any extent, whether or not substituted on the  
 460 phenyl ring to any extent, including, but not limited to:

- 461 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
- 462 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
- 463 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
- 464 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
- 465 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
- 466 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
- 467 (VII) Cannabipiperidiethanone.
- 468 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-  
 469 methoxyphenylacetyl)indole).

470 f. Cyclohexylphenols.—Any compound containing a  
 471 cyclohexylphenol structure, with or without substitution at the  
 472 5-position of the phenolic ring to any extent, whether or not  
 473 substituted on the cyclohexyl ring to any extent, including, but  
 474 not limited to:

- 475 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-

HB 1323

2022

476 yl)phenol).

477 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)

478 homologue).

479 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-

480 methyloctan-2-yl)phenol).

481 g. Benzoylindoles and Benzoylindazoles.—Any compound

482 containing a benzoylindole or benzoylindazole structure, with or

483 without substitution on the indole or indazole ring to any

484 extent, whether or not substituted on the phenyl ring to any

485 extent, including, but not limited to:

486 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

487 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

488 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-

489 iodo-5-nitrobenzoyl)indole).

490 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-

491 (4-methoxybenzoyl)indole).

492 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-

493 iodobenzoyl)indole).

494 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

495 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-

496 methoxybenzoyl)indole).

497 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-

498 3-(4-methoxybenzoyl)indole).

499 h. Tetramethylcyclopropanoylindoles and

500 Tetramethylcyclopropanoylindazoles.—Any compound containing a

HB 1323

2022

501 tetramethylcyclopropanoylindole or  
 502 tetramethylcyclopropanoylindazole structure, with or without  
 503 substitution on the indole or indazole ring to any extent,  
 504 whether or not substituted on the tetramethylcyclopropyl group  
 505 to any extent, including, but not limited to:

506 (I) UR-144 (1-Pentyl-3-(2,2,3,3-  
 507 tetramethylcyclopropanoyl)indole).

508 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
 509 tetramethylcyclopropanoyl)indole).

510 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-  
 511 tetramethylcyclopropanoyl)indole).

512 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-  
 513 tetramethylcyclopropanoyl)indole).

514 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-  
 515 tetramethylcyclopropanoyl)indole).

516 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-  
 517 tetramethylcyclopropanoyl)indole).

518 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-  
 519 tetramethylcyclopropanoyl)indole).

520 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
 521 tetramethylcyclopropanoyl)indazole).

522 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-  
 523 tetramethylcyclopropanoyl)indole).

524 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-  
 525 tetramethylcyclopropanoyl)indole).

HB 1323

2022

526 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole  
 527 carboxamides, and Adamantylindazole carboxamides.—Any compound  
 528 containing an adamantoyl indole, adamantoyl indazole, adamantyl  
 529 indole carboxamide, or adamantyl indazole carboxamide structure,  
 530 with or without substitution on the indole or indazole ring to  
 531 any extent, whether or not substituted on the adamantyl ring to  
 532 any extent, including, but not limited to:

533 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).

534 (II) Fluoro AKB48 (N-Adamant-1-yl 1-  
 535 (fluoropentyl)indazole-3-carboxamide).

536 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-  
 537 carboxamide).

538 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-  
 539 adamantoyl)indole).

540 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

541 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).

542 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-  
 543 adamantoyl)indole).

544 j. Quinolinyndolecarboxylates,  
 545 Quinolinyndazolecarboxylates, Quinolinyndolecarboxamides,  
 546 and Quinolinyndazolecarboxamides.—Any compound containing a  
 547 quinolinyndole carboxylate, quinolinyndazole carboxylate,  
 548 isoquinolinyndole carboxylate, isoquinolinyndazole  
 549 carboxylate, quinolinyndole carboxamide, quinolinyndazole  
 550 carboxamide, isoquinolinyndole carboxamide, or

HB 1323

2022

551 isoquinolinylindazole carboxamide structure, with or without  
552 substitution on the indole or indazole ring to any extent,  
553 whether or not substituted on the quinoline or isoquinoline ring  
554 to any extent, including, but not limited to:

555 (I) PB-22 (8-Quinoliny 1-pentylindole-3-carboxylate).

556 (II) Fluoro PB-22 (8-Quinoliny 1-(fluoropentyl)indole-3-  
557 carboxylate).

558 (III) BB-22 (8-Quinoliny 1-(cyclohexylmethyl)indole-3-  
559 carboxylate).

560 (IV) FUB-PB-22 (8-Quinoliny 1-(4-fluorobenzyl)indole-3-  
561 carboxylate).

562 (V) NPB-22 (8-Quinoliny 1-pentylindazole-3-carboxylate).

563 (VI) Fluoro NPB-22 (8-Quinoliny 1-(fluoropentyl)indazole-  
564 3-carboxylate).

565 (VII) FUB-NPB-22 (8-Quinoliny 1-(4-fluorobenzyl)indazole-  
566 3-carboxylate).

567 (VIII) THJ (8-Quinoliny 1-pentylindazole-3-carboxamide).

568 (IX) Fluoro THJ (8-Quinoliny 1-(fluoropentyl)indazole-3-  
569 carboxamide).

570 k. Naphthylindolecarboxylates and  
571 Naphthylindazolecarboxylates.—Any compound containing a  
572 naphthylindole carboxylate or naphthylindazole carboxylate  
573 structure, with or without substitution on the indole or  
574 indazole ring to any extent, whether or not substituted on the  
575 naphthyl ring to any extent, including, but not limited to:

HB 1323

2022

576 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-  
577 carboxylate).

578 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-  
579 carboxylate).

580 (III) Fluoro SDB-005 (1-Naphthalenyl 1-  
581 (fluoropentyl)indazole-3-carboxylate).

582 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-  
583 carboxylate).

584 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-  
585 carboxylate).

586 1. Naphthylindole carboxamides and Naphthylindazole  
587 carboxamides.—Any compound containing a naphthylindole  
588 carboxamide or naphthylindazole carboxamide structure, with or  
589 without substitution on the indole or indazole ring to any  
590 extent, whether or not substituted on the naphthyl ring to any  
591 extent, including, but not limited to:

592 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).

593 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-  
594 (fluoropentyl)indole-3-carboxamide).

595 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-  
596 (chloropentyl)indole-3-carboxamide).

597 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-  
598 carboxamide).

599 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-  
600 (fluoropentyl)indazole-3-carboxamide).



HB 1323

2022

601 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl  
 602 indazole carboxamides, Alkylcarbonyl indole carboxylates, and  
 603 Alkylcarbonyl indazole carboxylates.—Any compound containing an  
 604 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,  
 605 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-  
 606 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an  
 607 indole carboxamide, indazole carboxamide, indole carboxylate, or  
 608 indazole carboxylate, with or without substitution on the indole  
 609 or indazole ring to any extent, whether or not substituted on  
 610 the alkylcarbonyl group to any extent, including, but not  
 611 limited to:

612 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
 613 pentylindole-3-carboxamide).

614 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
 615 yl)-1-(fluoropentyl)indole-3-carboxamide).

616 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-  
 617 1-(fluoropentyl)indole-3-carboxamide).

618 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
 619 pentylindazole-3-carboxamide).

620 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-  
 621 yl)-1-(fluoropentyl)indazole-3-carboxamide).

622 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-  
 623 1-pentylindazole-3-carboxamide).

624 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-  
 625 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).

HB 1323

2022

- 626 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-  
 627 1-(4-fluorobenzyl)indazole-3-carboxamide).
- 628 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
 629 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
- 630 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
 631 (cyclohexylmethyl)indazole-3-carboxamide).
- 632 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-  
 633 1-(cyclohexylmethyl)indazole-3-carboxamide).
- 634 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
 635 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
- 636 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
 637 pentylindazole-3-carboxamide).
- 638 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-  
 639 1-(fluoropentyl)indazole-3-carboxamide).
- 640 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-  
 641 fluorobenzyl)indazole-3-carboxamide).
- 642 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
 643 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
- 644 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-  
 645 oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
- 646 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
 647 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
- 648 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-  
 649 fluoropentyl)indole-3-carboxamide).
- 650 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-

HB 1323

2022

651 fluoropentyl)indazole-3-carboxamide).

652 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-  
653 (cyclohexylmethyl)indazole-3-carboxamide).

654 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-  
655 fluorobenzyl)indazole-3-carboxamide).

656 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
657 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).

658 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—  
659 Any compound containing a N-(2-phenylpropan-2-yl) indole  
660 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide  
661 structure, with or without substitution on the indole or  
662 indazole ring to any extent, whether or not substituted on the  
663 phenyl ring of the cumyl group to any extent, including, but not  
664 limited to:

665 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-  
666 carboxamide).

667 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-  
668 (fluoropentyl)indole-3-carboxamide).

669 o. Other Synthetic Cannabinoids.—Any material, compound,  
670 mixture, or preparation that contains any quantity of a  
671 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

672 (I) With or without modification or replacement of a  
673 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage  
674 between either two core rings, or linkage between a core ring  
675 and group structure, with or without the addition of a carbon or

HB 1323

2022

676 replacement of a carbon;  
 677 (II) With or without replacement of a core ring or group  
 678 structure, whether or not substituted on the ring or group  
 679 structures to any extent; and  
 680 (III) Is a cannabinoid receptor agonist, unless  
 681 specifically excepted or unless listed in another schedule or  
 682 contained within a pharmaceutical product approved by the United  
 683 States Food and Drug Administration.  
 684 191. Substituted Cathinones.—Unless specifically excepted,  
 685 listed in another schedule, or contained within a pharmaceutical  
 686 product approved by the United States Food and Drug  
 687 Administration, any material, compound, mixture, or preparation,  
 688 including its salts, isomers, esters, or ethers, and salts of  
 689 isomers, esters, or ethers, whenever the existence of such salts  
 690 is possible within any of the following specific chemical  
 691 designations:  
 692 a. Any compound containing a 2-amino-1-phenyl-1-propanone  
 693 structure;  
 694 b. Any compound containing a 2-amino-1-naphthyl-1-  
 695 propanone structure; or  
 696 c. Any compound containing a 2-amino-1-thiophenyl-1-  
 697 propanone structure,  
 698  
 699 whether or not the compound is further modified:  
 700 (I) With or without substitution on the ring system to any

HB 1323

2022

701 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,  
 702 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused  
 703 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide  
 704 substituents;

705 (II) With or without substitution at the 3-propanone  
 706 position with an alkyl substituent or removal of the methyl  
 707 group at the 3-propanone position;

708 (III) With or without substitution at the 2-amino nitrogen  
 709 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or  
 710 not further substituted in the ring system; or

711 (IV) With or without inclusion of the 2-amino nitrogen  
 712 atom in a cyclic structure, including, but not limited to:

- 713 (A) Methcathinone.
- 714 (B) Ethcathinone.
- 715 (C) Methylone (3,4-Methylenedioxy-methcathinone).
- 716 (D) 2,3-Methylenedioxy-methcathinone.
- 717 (E) MDPV (3,4-Methylenedioxy-pyrovalerone).
- 718 (F) Methylmethcathinone.
- 719 (G) Methoxymethcathinone.
- 720 (H) Fluoromethcathinone.
- 721 (I) Methylethcathinone.
- 722 (J) Butylone (3,4-Methylenedioxy-alpha-  
 723 methylaminobutyrophenone).
- 724 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 725 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).

HB 1323

2022

- 726 (M) Naphyrone (Naphthylpyrovalerone).
- 727 (N) Bromomethcathinone.
- 728 (O) Buphedrone (alpha-Methylaminobutyrophenone).
- 729 (P) Eutylone (3,4-Methylenedioxy-alpha-
- 730 ethylaminobutyrophenone).
- 731 (Q) Dimethylcathinone.
- 732 (R) Dimethylmethcathinone.
- 733 (S) Pentylone (3,4-Methylenedioxy-alpha-
- 734 methylaminovalerophenone).
- 735 (T) Pentedrone (alpha-Methylaminovalerophenone).
- 736 (U) MDPPP (3,4-Methylenedioxy-alpha-
- 737 pyrrolidinopropiophenone).
- 738 (V) MDPBP (3,4-Methylenedioxy-alpha-
- 739 pyrrolidinobutyrophenone).
- 740 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 741 (X) PPP (Pyrrolidinopropiophenone).
- 742 (Y) PVP (Pyrrolidinovalerophenone) or
- 743 (Pyrrolidinopentiophenone).
- 744 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
- 745 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 746 (BB) F-MABP (Fluoromethylaminobutyrophenone).
- 747 (CC) Me-EABP (Methylethylaminobutyrophenone).
- 748 (DD) PBP (Pyrrolidinobutyrophenone).
- 749 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 750 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).

HB 1323

2022

751 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).  
 752 (HH) Dimethylone (3,4-Methylenedioxy-N,N-  
 753 dimethylcathinone).  
 754 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.  
 755 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.  
 756 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.  
 757 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.  
 758 (MM) Methylbuphedrone (Methyl-alpha-  
 759 methylaminobutyrophenone).  
 760 (NN) Methyl-alpha-methylaminohexanophenone.  
 761 (OO) N-Ethyl-N-methylcathinone.  
 762 (PP) PHP (Pyrrolidinohexanophenone).  
 763 (QQ) PV8 (Pyrrolidinoheptanophenone).  
 764 (RR) Chloromethcathinone.  
 765 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.  
 766 192. Substituted Phenethylamines.—Unless specifically  
 767 excepted or unless listed in another schedule, or contained  
 768 within a pharmaceutical product approved by the United States  
 769 Food and Drug Administration, any material, compound, mixture,  
 770 or preparation, including its salts, isomers, esters, or ethers,  
 771 and salts of isomers, esters, or ethers, whenever the existence  
 772 of such salts is possible within any of the following specific  
 773 chemical designations, any compound containing a phenethylamine  
 774 structure, without a beta-keto group, and without a benzyl group  
 775 attached to the amine group, whether or not the compound is

HB 1323

2022

776 further modified with or without substitution on the phenyl ring  
 777 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,  
 778 halide, fused alkylenedioxy, fused furan, fused benzofuran,  
 779 fused dihydrofuran, or fused tetrahydropyran substituents,  
 780 whether or not further substituted on a ring to any extent, with  
 781 or without substitution at the alpha or beta position by any  
 782 alkyl substituent, with or without substitution at the nitrogen  
 783 atom, and with or without inclusion of the 2-amino nitrogen atom  
 784 in a cyclic structure, including, but not limited to:

- 785 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 786 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 787 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 788 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 789 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 790 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 791 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 792 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 793 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 794 j. 2C-H (2,5-Dimethoxyphenethylamine).
- 795 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 796 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 797 m. MDMA (3,4-Methylenedioxyamphetamine).
- 798 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
- 799 Methylenedioxy-N-methylbutanamine).
- 800 o. MDA (3,4-Methylenedioxyamphetamine).



HB 1323

2022

- 801 p. 2,5-Dimethoxyamphetamine.
- 802 q. Fluoroamphetamine.
- 803 r. Fluoromethamphetamine.
- 804 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 805 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 806 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 807 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
- 808 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 809 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 810 y. PMA (4-Methoxyamphetamine).
- 811 z. N-Ethylamphetamine.
- 812 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 813 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 814 cc. PMMA (4-Methoxymethamphetamine).
- 815 dd. N,N-Dimethylamphetamine.
- 816 ee. 3,4,5-Trimethoxyamphetamine.
- 817 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
- 818 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
- 819 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
- 820 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
- 821 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 822 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 823 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 824 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 825 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).

HB 1323

2022

826 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).  
 827 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).  
 828 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).  
 829 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).  
 830 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-  
 831 dihydrobenzofuran),

832  
 833 which does not include phenethylamine, mescaline as described in  
 834 subparagraph 20., substituted cathinones as described in  
 835 subparagraph 191., N-Benzyl phenethylamine compounds as  
 836 described in subparagraph 193., or methamphetamine as described  
 837 in subparagraph (2)(c)5.

838 193. N-Benzyl Phenethylamine Compounds.—Unless  
 839 specifically excepted or unless listed in another schedule, or  
 840 contained within a pharmaceutical product approved by the United  
 841 States Food and Drug Administration, any material, compound,  
 842 mixture, or preparation, including its salts, isomers, esters,  
 843 or ethers, and salts of isomers, esters, or ethers, whenever the  
 844 existence of such salts is possible within any of the following  
 845 specific chemical designations, any compound containing a  
 846 phenethylamine structure without a beta-keto group, with  
 847 substitution on the nitrogen atom of the amino group with a  
 848 benzyl substituent, with or without substitution on the phenyl  
 849 or benzyl ring to any extent with alkyl, alkoxy, thio,  
 850 alkylthio, halide, fused alkylenedioxy, fused furan, fused

HB 1323

2022

851 benzofuran, or fused tetrahydropyran substituents, whether or  
 852 not further substituted on a ring to any extent, with or without  
 853 substitution at the alpha position by any alkyl substituent,  
 854 including, but not limited to:

855 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-  
 856 methoxybenzyl)]phenethylamine).

857 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-  
 858 hydroxybenzyl)]phenethylamine).

859 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-  
 860 fluorobenzyl)]phenethylamine).

861 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-  
 862 methylenedioxybenzyl)]phenethylamine).

863 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-  
 864 methoxybenzyl)]phenethylamine).

865 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-  
 866 hydroxybenzyl)]phenethylamine).

867 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-  
 868 fluorobenzyl)]phenethylamine).

869 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-  
 870 methylenedioxybenzyl)]phenethylamine).

871 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-  
 872 methoxybenzyl)]phenethylamine).

873 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-  
 874 methoxybenzyl)]phenethylamine).

875 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-

HB 1323

2022

876 methoxybenzyl) ]phenethylamine) .

877       l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-  
878 methoxybenzyl) ]phenethylamine) .

879       m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-  
880 hydroxybenzyl) ]phenethylamine) .

881       n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-  
882 fluorobenzyl) ]phenethylamine) .

883       o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-  
884 methylenedioxybenzyl) ]phenethylamine) .

885       p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-  
886 methoxybenzyl) ]phenethylamine) .

887       q. 25H-NBOH (2,5-Dimethoxy-[N-(2-  
888 hydroxybenzyl) ]phenethylamine) .

889       r. 25H-NBF (2,5-Dimethoxy-[N-(2-  
890 fluorobenzyl) ]phenethylamine) .

891       s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-  
892 methoxybenzyl) ]phenethylamine) ,

893

894 which does not include substituted cathinones as described in  
895 subparagraph 191.

896       194. Substituted Tryptamines.—Unless specifically excepted  
897 or unless listed in another schedule, or contained within a  
898 pharmaceutical product approved by the United States Food and  
899 Drug Administration, any material, compound, mixture, or  
900 preparation containing a 2-(1H-indol-3-yl)ethanamine, for

HB 1323

2022

901 example tryptamine, structure with or without mono- or di-  
 902 substitution of the amine nitrogen with alkyl or alkenyl groups,  
 903 or by inclusion of the amino nitrogen atom in a cyclic  
 904 structure, whether or not substituted at the alpha position with  
 905 an alkyl group, whether or not substituted on the indole ring to  
 906 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy  
 907 groups, including, but not limited to:

- 908 a. Alpha-Ethyltryptamine.
- 909 b. Bufotenine.
- 910 c. DET (Diethyltryptamine).
- 911 d. DMT (Dimethyltryptamine).
- 912 e. MET (N-Methyl-N-ethyltryptamine).
- 913 f. DALT (N,N-Diallyltryptamine).
- 914 g. EiPT (N-Ethyl-N-isopropyltryptamine).
- 915 h. MiPT (N-Methyl-N-isopropyltryptamine).
- 916 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 917 j. 5-Hydroxy-N-methyltryptamine.
- 918 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 919 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 920 m. Methyltryptamine.
- 921 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 922 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
- 923 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 924 q. DiPT (N,N-Diisopropyltryptamine).
- 925 r. DPT (N,N-Dipropyltryptamine).

HB 1323

2022

- 926 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 927 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 928 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
- 929 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
- 930 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
- 931 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
- 932 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-
- 933 isopropyltryptamine).
- 934 z. Methyl-alpha-ethyltryptamine.
- 935 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),

936  
 937 which does not include tryptamine, psilocyn as described in  
 938 subparagraph 34., or psilocybin as described in subparagraph 33.

939 195. Substituted Phenylcyclohexylamines.—Unless  
 940 specifically excepted or unless listed in another schedule, or  
 941 contained within a pharmaceutical product approved by the United  
 942 States Food and Drug Administration, any material, compound,  
 943 mixture, or preparation containing a phenylcyclohexylamine  
 944 structure, with or without any substitution on the phenyl ring,  
 945 any substitution on the cyclohexyl ring, any replacement of the  
 946 phenyl ring with a thiophenyl or benzothiophenyl ring, with or  
 947 without substitution on the amine with alkyl, dialkyl, or alkoxy  
 948 substituents, inclusion of the nitrogen in a cyclic structure,  
 949 or any combination of the above, including, but not limited to:

- 950 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP

HB 1323

2022

- 951 (Benocyclidine).
- 952 b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog
- 953 of phencyclidine).
- 954 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
- 955 analog of phencyclidine).
- 956 d. PCPr (Phenylcyclohexylpropylamine).
- 957 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene
- 958 analog of phencyclidine).
- 959 f. PCEEA (Phenylcyclohexyl (ethoxyethylamine)).
- 960 g. PCMPA (Phenylcyclohexyl (methoxypropylamine)).
- 961 h. Methoxetamine.
- 962 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
- 963 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
- 964 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
- 965 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
- 966 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
- 967 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
- 968 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
- 969 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
- 970 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
- 971 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
- 972 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-
- 973 piperidinylidene]-benzenesulfonamide.
- 974 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-
- 975 piperidinylidene]-benzenesulfonamide.

HB 1323

2022

976 198. AH-7921, 3,4-dichloro-N-[[1-  
 977 (dimethylamino)cyclohexyl)methyl]-benzamide.

978 199. U47700, trans-3,4-dichloro-N-[2-  
 979 (dimethylamino)cyclohexyl]-N-methyl-benzamide.

980 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,  
 981 dihydrochloride.

982 Section 2. This act does not limit the authority of the  
 983 Attorney General pursuant to s. 893.035 or s. 893.0355, Florida  
 984 Statutes.

985 Section 3. This act shall take effect upon becoming a law.